<DOC>
	<DOCNO>NCT00773838</DOCNO>
	<brief_summary>Study vorinostat combination bortezomib patient relapse refractory multiple myeloma least 2 prior treatment regimen . Histone deacetylases ( HDAC ) facilitate gene transcription modulate uncoiling chromatin . HDAC function dysregulated hematologic solid malignancy , dysregulation may result over-expression oncogene . Thus , inhibition HDACs may result anti-cancer effect . HDAC inhibitor , like vorinostat , represent new class antitumor agent ability induce antiproliferative effect include cyto-differentiation , cell cycle growth arrest apoptosis various cancer cell line . Several study investigate vitro antimyeloma activity vorinostat combination bortezomib demonstrate vorinostat may act synergistically bortezomib modulate tumor cell growth . Mitsiades et al show vorinostat enhances sensitivity bortezomib . Pei et al find exposure human multiple myeloma cell line &amp; amp ; patient-derived multiple myeloma cell bortezomib vorinostat result synergistic interaction result : ( 1 ) Interruption NF-kB &amp; relate signaling pathway ( JNK , XIAP , Mcl-1 , etc . ) ( 2 ) Inhibition Hsp90 ( 3 ) Induction ER stress signal ( 4 ) acetylation Dynein/ disruption aggresome function/formation , salvage ubiquitinated protein . In addition mark increase mitochondrial injury , caspase activation , apoptosis also observe . Bortezomib indicate treatment patient multiple myeloma . Two Phase I dose-ranging study regimen combine vorinostat bortezomib among patient relapse well end-stage , refractory multiple myeloma conduct . These study enrol total 57 patient . In study , administration vorinostat standard dos bortezomib result response 20/45 ( 44 % ) evaluable patient ( Weber et al 2007 , Badros et al 2007 ) . The purpose present study definitively evaluate clinical activity vorinostat combination bortezomib patient multiple myeloma . Based preliminary safety &amp; efficacy present Weber et al Badros et al ASH 2007 , protocol evaluate clinical activity vorinostat multiple myeloma .</brief_summary>
	<brief_title>Study Vorinostat ( MK0683 ) , HDAC Inhibitor , Combination With Bortezomib Patients With Relapsed Refractory Multiple Myeloma ( 0683-095 AMJ )</brief_title>
	<detailed_description>The protocol amend incorporate language indicate end study . The end study designate time primary endpoint 29 responder meet , time patient discontinue treatment enrol study least 6 month ( primary endpoint reach time ) . Patients allow continue protocol long meet criterion discontinuation .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Patient 18 year age old Patient establish diagnosis multiple myeloma base myeloma diagnostic criterion Patient must adequate organ function Patient refractory prior bortezomib regimen also expose prior IMiD ( thalidimide lenalidmide ) Patient relapse refractory multiple myeloma l 2 prior treatment regimens Patient relapse , refractory , intolerant , and/or ineligible ( opinion investigator ) therapies include IMiD ( thalidomide OR lenalidomide ) Patient refractory bortezomib ( response prior bortezomib contain regimen progression within 60 day bortezomib contain regimen Patient know hypersensitivity component bortezomib vorinostat Patient prior allogeneic bone marrow transplant plan undergo type bone marrow transplantation within 4 week initiation study therapy Patient know hypersensitivity component bortezomib vorinostat Patient active Hepatitis B C , plasma cell leukemia , HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>